---
title: "Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine | SNGX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289047958.md"
description: "Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine | SNGX Stock News"
datetime: "2026-06-08T03:30:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289047958.md)
  - [en](https://longbridge.com/en/news/289047958.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289047958.md)
generator: "portal-rs"
---

# Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine | SNGX Stock News

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine | SNGX Stock News

### Related Stocks

- [SNGX.US](https://longbridge.com/en/quote/SNGX.US.md)

## Related News & Research

- [SOLIGENIX, INC. 3Q 2026: Revenue $0 EPS $(0.12) — 10-Q Summary](https://longbridge.com/en/news/295273764.md)
- [Congo set to receive 70,000 Ervebo vaccines to contain Ebola outbreak, WHO says](https://longbridge.com/en/news/296519322.md)
- [NanoViricides wins DRC ACOREP clearance for Phase II NV-387 Ebola treatment trial](https://longbridge.com/en/news/296228628.md)
- [The LGL Group, Inc. Announces Timing of Redomestication from Delaware to Nevada | LGL Stock News](https://longbridge.com/en/news/296396779.md)
- [Caesars CFO Bret Yunker sells 208,134 shares for $6.17 million](https://longbridge.com/en/news/296650683.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**